STXS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Stereotaxis Inc (STXS) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the stock has potential upside based on analyst ratings and its unique MedTech positioning, the lack of significant trading signals, declining financial performance, and absence of recent positive news or catalysts suggest a cautious approach. Holding the stock or waiting for further developments is advisable.
The MACD is positive and expanding, indicating a bullish momentum. RSI is neutral at 65.302, and moving averages are converging, showing no strong trend. The stock is trading near its resistance level (R1: 2.211), which might limit immediate upside potential.
Gross margin improved significantly YoY, reflecting better cost management.
Revenue dropped by 18.83% YoY in Q3 2025, and EPS declined by 12.50% YoY, signaling weakening financial performance. No recent news or significant insider/hedge fund activity to drive sentiment. Congress trading data is absent.
In Q3 2025, revenue declined to $7.46M (-18.83% YoY), and EPS dropped to -0.07 (-12.50% YoY). However, net income improved slightly (-$6.79M, up 4.10% YoY), and gross margin increased to 54.94% (+23.27% YoY), indicating some operational improvements.
Citizens initiated coverage with an Outperform rating and a $4 price target, citing the company's innovative MedTech solutions and potential for growth through 2026.
